|
About the WHITE PAPERS category
|
|
0
|
1019
|
February 8, 2016
|
|
Stability chambers
|
|
3
|
1354
|
May 8, 2018
|
|
A Validation Approach for LIMS
|
|
2
|
1190
|
March 12, 2014
|
|
Writing Effective Test Scripts
|
|
2
|
1162
|
April 3, 2013
|
|
How to achieve international action on falsified and substandard medicines
|
|
0
|
1093
|
November 20, 2012
|
|
50 Acronyms of the FDA
|
|
0
|
996
|
November 11, 2012
|
|
Alternative SWD Models to the V-Model
|
|
0
|
1044
|
June 14, 2012
|
|
Process validation latest guideline from USFDA
|
|
1
|
1186
|
March 21, 2012
|
|
Usfda guidelines
|
|
6
|
1662
|
March 10, 2012
|
|
Annex 11 Vs CFR's
|
|
2
|
1140
|
August 25, 2011
|
|
Latest guideline on SMF from PIC's
|
|
1
|
1162
|
July 25, 2011
|
|
Suppliar qualification latest guidelines from APIC
|
|
0
|
1122
|
May 31, 2011
|
|
Quality by Design for ANDA
|
|
5
|
1525
|
April 8, 2011
|
|
Link between sunlight and drug efficacy
|
|
0
|
1006
|
March 16, 2011
|
|
CMO consolidation
|
|
0
|
1023
|
March 15, 2011
|
|
Prequalification programme for selected APIs
|
|
0
|
876
|
March 12, 2011
|
|
$1.3bn average R&D cost per new drug
|
|
0
|
1030
|
March 12, 2011
|
|
Cancer trials biggest risk for Pharmas
|
|
0
|
1145
|
February 19, 2011
|
|
Fda mapp
|
|
0
|
1051
|
February 18, 2011
|
|
Huge step Forward by EU
|
|
0
|
1110
|
February 18, 2011
|
|
Method Validation
|
|
0
|
1252
|
February 10, 2011
|
|
Residual solvents
|
|
0
|
1159
|
February 7, 2011
|
|
Forced Degredation Studies
|
|
0
|
1037
|
February 7, 2011
|
|
GxP assessment form
|
|
4
|
2304
|
January 3, 2011
|
|
Retooling for Traceability: 10 Steps
|
|
0
|
978
|
December 25, 2010
|
|
Monographs Pharmacopoeias in Scribd
|
|
0
|
1562
|
December 16, 2010
|
|
Impurities in Pharmaceuticals
|
|
2
|
1148
|
December 9, 2010
|
|
Changes in European pharmacopoeia - Microbiology
|
|
0
|
1094
|
December 9, 2010
|
|
FDA launches global supply chain pilot scheme-News
|
|
0
|
1019
|
December 3, 2010
|
|
Guidelines needed for inconsistent OTC medication -News
|
|
0
|
1043
|
December 3, 2010
|